Brief: Hepion Pharmaceuticals Inc Says It Has Been Granted 180-Day Extension By Nasdaq To Meet The Minimum Bid Price Requirements
05/12/2022 21:47
Dec 5 (Reuters) - Hepion Pharmaceuticals Inc HEPA.O :
* HEPION PHARMACEUTICALS, INC. GRANTED 180-DAY EXTENSION BY
NASDAQ
TO MEET THE MINIMUM BID PRICE REQUIREMENTS
Source text for Eikon: ID:nGNX67J75L
Further company coverage: HEPA.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Hepion Pharmaceuticals
See all newsBrief: Hepion Pharmaceuticals Executes Binding Letter Of Intent With New Day Diagnostics To Commercialize Diagnostic Tests For Celiac Disease, Respiratory Multiplex, H. Pylori And Hcc
Brief: Hepion Pharma In-Licenses Diagnostic Tests from New Day Diagnostics- SEC Filing
Brief: Hepion Pharmaceuticals Announces Termination Of Merger Agreement With Pharma Two B
Brief: Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B
Brief: Pharma Two B Plans To Go Public Via Merger With Hepion Pharmaceuticals, Concurrent $11.5 Mln Private Placement